FRATTAROLI JOSEPH 4

4 · Inhibikase Therapeutics, Inc. · Filed Mar 3, 2023

Insider Transaction Report

Form 4
Period: 2023-03-01
FRATTAROLI JOSEPH
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-03-01+90,00090,000 total
    Exercise: $0.74Exp: 2023-03-01Common Stock (90,000 underlying)
Holdings
  • Common Stock

    48,091
Footnotes (1)
  • [F1]One-third of the options will vest and become exercisable on 3/1/2024, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2024, subject to continued employment through each such vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION